Phenylpropanolamine: toward resolution of a controversy.

This guest editorial comments on Miller's editorial on phenylpropanolamine (PPA), which was a response to an article by Morgan and coworkers. The Morgan study involved 837 adultes with varying degrees of obesity, in a multisite double-blind placebo comparison of PPA 75 mg sustained release and 25 mg immediate release three times daily. The conclusion of the 11 measurements of subjective was that euphoriant or stimulant effects characterizing drugs of abuse were not found in the subjects taking PPA compared to those on the placebo